752242-45-8

Basic information

• Product Name: 3-hydroxy-5-(4-methanesulfonylphenoxy)benzoic acid methyl ester
• Synonyms: 3-hydroxy-5-(4-methanesulfonylphenoxy)benzoic acid methyl ester
• CAS NO: 752242-45-8
• Molecular Weight: 322.339
• Mol File: 752242-45-8.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 3-hydroxy-5-(4-methanesulfonylphenoxy)benzoic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-hydroxy-5-(4-methanesulfonylphenoxy)benzoic acid methyl ester(752242-45-8)
• EPA Substance Registry System: 3-hydroxy-5-(4-methanesulfonylphenoxy)benzoic acid methyl ester(752242-45-8)

Safety Data

• Hazardous Substances Data: 752242-45-8(Hazardous Substances Data)

Upstream product

• 54915-31-0 methyl 3-(benzyloxy)-5-hydroxybenzoate 
• 2150-44-9 1-carbomethoxy-3,5-dihydroxybenzene 
• 3466-32-8 4-bromoohenyl methyl sulfone 
• 117095-72-4 (4-fluorophenyl)methyl sulfone 
• 871656-49-4 methyl 3-(benzyloxy)-5-(4-(methylsulfonyl)phenoxy)benzoate 
• 752242-43-6 3-(4-methanesulfonyl-phenoxy)-5-methoxymethoxy-benzoic acid methyl ester 
• 455-15-2 1-(methylsufonyl)-4-fluorobenzene 

Downstream Products

• 863504-76-1 methyl 3-[(1S)-2-methoxy-1-(methylethyl)oxy]-5-{[4-(methylsulfonyl)phenyl]oxy}benzoate 
• 1001419-56-2 C₃₄H₃₈O₇SSi 
• 1001419-66-4 C₂₅H₂₆O₇S 
• 1001419-98-2 C₁₇H₁₆O₇S 
• 1001419-99-3 C₁₈H₁₇NO₈S 
• 1001420-25-2 C₁₉H₂₀O₇S 
• 752242-47-0 5-((1S)-2-(tert-butyldimethylsiloxy)-1-methylethoxy)-3-(4-methanesulfonylphenoxy)benzoic acid methyl ester 
• 939054-40-7 methyl 3-((3-methylpyridin-2-yl)methoxy)-5-(4-(methylsulfonyl)phenoxy) benzoate 
• 752241-83-1 methyl 3-isopropoxy-5-(4-(methylsulfonyl)phenoxy)benzoate 
• 1001420-89-8 C₁₉H₁₅NO₆S 
• 1107062-21-4 C₃₁H₃₂O₆SSi 
• 1235567-13-1 3-(4-methanesulfonylphenoxy)-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)benzoic acid methyl ester 
• 1596340-67-8 3-(4-methanesulfonylphenoxy)-5-(3-methylpyridin-2-yl)benzoic acid methyl ester 
• 1596340-68-9 3-(4-methanesulfonylphenoxy)-5-(3-methylpyridin-2-yl)benzoic acid 

Relevant articles and documents

Discovery of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific glucokinase activators: Design, synthesis, and biological evaluation

Glucokinase (GK) activators are being developed for the treatment of type 2 diabetes mellitus (T2DM). However, existing GK activators have risks of hypoglycemia caused by over-activation of GK in islet cells and dyslipidemia caused by over-activation of intrahepatic GK. In the effort to mitigate risks of hypoglycemia and dyslipidemia while maintaining the promising efficacy of GK activator, we investigated a series of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific partial GK activators, which led to the identification of compound 72 that showed a good balance between in vitro potency and enzyme kinetic parameters, and protected β-cells from streptozotocin-induced apoptosis. Chronic treatment of compound 72 demonstrated its potent activity in regulation of glucose homeostasis and low risk of dyslipidemia with diabetic db/db mice in oral glucose tolerance test (OGTT). Moreover, acute treatment of compound 72 did not induce hypoglycemia in C57BL/6J mice even at 200 mg/kg via oral administration.

NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME

Compounds are provided which are phosphonate and phosphinate activators and thus are useful in treating diabetes and related diseases and have the structure wherein is a heteroaryl ring; R4 is —(CH2)n-Z-(CH2)m—PO(OR7)(OR8), —(CH2)nZ-(CH2)m—PO(OR7)Rg, —(CH2)n-Z-(CH2)m—OPO(OR7)Rg, —(CH2)nZ—(CH2)m—OPO(R9)(R10), or —(CH2)nZ—(CH2)m—PO(R9)(R10);R5 and R6 are independently selected from H, alkyl and halogen;Y is R7(CH2)s or is absent; andX, n, Z, m, R4, R5, R6, R7, and s are as defined herein; or a pharmaceutically acceptable salt thereof. A method for treating diabetes and related diseases employing the above compounds is also provided.

HETEROARYLCARBAMOYLBENZENE DERIVATIVE

Compounds having glucokinase activating effects and being useful as treatments for diabetes, which are represented by the following formula (I): [wherein X1 represents oxygen, etc., X2 represents oxygen, etc., R1 represents a group on Ring A such as alkylsulfonyl, etc., R2 represents C3-7 cyclic alkyl optionally substituted with a halogen, etc., R3 represents a substituent on Ring B such as lower alkyl, etc., formula (II): represents 6- to 10-membered aryl, etc., and formula (III): represents monocyclic or bicyclic heteroaryl optionally having on Ring B a substituent represented by R3 above, wherein the carbon atom of Ring B which is bonded to the nitrogen atom of the amide group of formula (I) forms a C=N bond with the nitrogen atom of the ring], as well as their pharmaceutically acceptable salts.